From: Evaluation of in vivo labelled dendritic cell migration in cancer patients
Patients | mDC × 106 | Administration route | Isotope | Max uptake (%) * |
---|---|---|---|---|
R.L. (no. 7) | 4 | Intradermal | 99m Tc-HMPAO | 0.95 |
G.D. (no. 8) | 4 | Intradermal | 99m Tc-HMPAO | 1.02 |
R.L. (no. 7) | 4 | Subcutaneous | 99m Tc-HMPAO | 0.30 |
G.D. (no. 8) | 4 | Subcutaneous | 99m Tc-HMPAO | 0.37 |